{"address1": "One Amgen Center Drive", "city": "Thousand Oaks", "state": "CA", "zip": "91320-1799", "country": "United States", "phone": "805 447 1000", "fax": "805 447 1010", "website": "https://www.amgen.com", "industry": "Drug Manufacturers\u2014General", "industryDisp": "Drug Manufacturers\u2014General", "sector": "Healthcare", "longBusinessSummary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh\u00e7et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.", "fullTimeEmployees": 25200, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert A. Bradway", "age": 59, "title": "Chairman, CEO & Pres", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": 5487475, "exercisedValue": 0, "unexercisedValue": 43693576}, {"maxAge": 1, "name": "Mr. Peter H. Griffith", "age": 63, "title": "Exec. VP & CFO", "yearBorn": 1959, "fiscalYear": 2022, "totalPay": 2574004, "exercisedValue": 0, "unexercisedValue": 245771}, {"maxAge": 1, "name": "Mr. Esteban  Santos", "age": 54, "title": "Exec. VP of Operations", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 2521941, "exercisedValue": 0, "unexercisedValue": 8232750}, {"maxAge": 1, "name": "Dr. David M. Reese M.D.", "age": 59, "title": "Exec. VP of R&D", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": 2833393, "exercisedValue": 0, "unexercisedValue": 4932458}, {"maxAge": 1, "name": "Mr. Murdo  Gordon", "age": 55, "title": "Exec. VP of Global Commercial Operations", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": 2717562, "exercisedValue": 0, "unexercisedValue": 2469817}, {"maxAge": 1, "name": "Ms. Linda H. Louie", "title": "VP of Fin. & Chief Accounting Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mike  Zahigian", "title": "Sr. VP & Chief Information Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Arvind  Sood", "title": "VP of Investor Relations", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan P. Graham", "age": 61, "title": "Exec. VP, Gen. Counsel & Sec.", "yearBorn": 1961, "fiscalYear": 2019, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Nancy A. Grygiel", "age": 54, "title": "Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer", "yearBorn": 1968, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 8, "compensationRisk": 1, "shareHolderRightsRisk": 1, "overallRisk": 1, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 234.43, "open": 234.89, "dayLow": 231.348, "dayHigh": 235.0, "regularMarketPreviousClose": 234.43, "regularMarketOpen": 234.89, "regularMarketDayLow": 231.348, "regularMarketDayHigh": 235.0, "dividendRate": 8.52, "dividendYield": 0.0363, "exDividendDate": 1684281600, "payoutRatio": 0.5404, "fiveYearAvgDividendYield": 2.87, "beta": 0.641097, "trailingPE": 15.915024, "forwardPE": 12.426221, "volume": 1412796, "regularMarketVolume": 1412796, "averageVolume": 2295038, "averageVolume10days": 2247590, "averageDailyVolume10Day": 2247590, "bid": 0.0, "ask": 0.0, "bidSize": 800, "askSize": 1100, "marketCap": 125091299328, "fiftyTwoWeekLow": 223.3, "fiftyTwoWeekHigh": 296.67, "priceToSalesTrailing12Months": 4.7763, "fiftyDayAverage": 238.8792, "twoHundredDayAverage": 251.25415, "trailingAnnualDividendRate": 7.95, "trailingAnnualDividendYield": 0.033912044, "currency": "USD", "enterpriseValue": 155296186368, "profitMargins": 0.30229, "floatShares": 533215195, "sharesOutstanding": 534327008, "sharesShort": 7613222, "sharesShortPriorMonth": 7833483, "sharesShortPreviousMonthDate": 1680220800, "dateShortInterest": 1682640000, "sharesPercentSharesOut": 0.014199999, "heldPercentInsiders": 0.0021600001, "heldPercentInstitutions": 0.79827005, "shortRatio": 3.72, "shortPercentOfFloat": 0.0143, "impliedSharesOutstanding": 0, "bookValue": 10.009, "priceToBook": 23.38995, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1680220800, "earningsQuarterlyGrowth": 0.925, "netIncomeToCommon": 7917000192, "trailingEps": 14.71, "forwardEps": 18.84, "pegRatio": 7.65, "lastSplitFactor": "2:1", "lastSplitDate": 943228800, "enterpriseToRevenue": 5.93, "enterpriseToEbitda": 11.835, "52WeekChange": -0.025806189, "SandP52WeekChange": 0.046755195, "lastDividendValue": 2.13, "lastDividendDate": 1676332800, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "AMGN", "underlyingSymbol": "AMGN", "shortName": "Amgen Inc.", "longName": "Amgen Inc.", "firstTradeDateEpochUtc": 424704600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9376b97e-b428-3231-ba0b-142b20481cb4", "messageBoardId": "finmb_24816", "gmtOffSetMilliseconds": -14400000, "currentPrice": 234.11, "targetHighPrice": 325.0, "targetLowPrice": 175.0, "targetMeanPrice": 256.29, "targetMedianPrice": 265.0, "recommendationMean": 2.7, "recommendationKey": "hold", "numberOfAnalystOpinions": 21, "totalCash": 31561000960, "totalCashPerShare": 59.067, "ebitda": 13121999872, "totalDebt": 61595000832, "quickRatio": 2.624, "currentRatio": 3.145, "totalRevenue": 26190000128, "debtToEquity": 1151.739, "revenuePerShare": 48.999, "returnOnAssets": 0.081520006, "returnOnEquity": 2.52778, "grossProfits": 19917000000, "freeCashflow": 7954999808, "operatingCashflow": 8620999680, "earningsGrowth": 0.97, "revenueGrowth": -0.021, "grossMargins": 0.74933, "ebitdaMargins": 0.50103, "operatingMargins": 0.36831, "financialCurrency": "USD", "trailingPegRatio": 1.2905}